1. Home
  2. URGN vs ALNT Comparison

URGN vs ALNT Comparison

Compare URGN & ALNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • ALNT
  • Stock Information
  • Founded
  • URGN 2004
  • ALNT 1962
  • Country
  • URGN United States
  • ALNT United States
  • Employees
  • URGN N/A
  • ALNT N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • ALNT Electrical Products
  • Sector
  • URGN Health Care
  • ALNT Industrials
  • Exchange
  • URGN Nasdaq
  • ALNT Nasdaq
  • Market Cap
  • URGN 465.9M
  • ALNT 404.8M
  • IPO Year
  • URGN 2017
  • ALNT N/A
  • Fundamental
  • Price
  • URGN $10.08
  • ALNT $26.59
  • Analyst Decision
  • URGN Strong Buy
  • ALNT Strong Buy
  • Analyst Count
  • URGN 6
  • ALNT 3
  • Target Price
  • URGN $42.25
  • ALNT $31.00
  • AVG Volume (30 Days)
  • URGN 308.1K
  • ALNT 73.6K
  • Earning Date
  • URGN 03-13-2025
  • ALNT 03-05-2025
  • Dividend Yield
  • URGN N/A
  • ALNT 0.45%
  • EPS Growth
  • URGN N/A
  • ALNT N/A
  • EPS
  • URGN N/A
  • ALNT 0.87
  • Revenue
  • URGN $89,363,000.00
  • ALNT $548,955,000.00
  • Revenue This Year
  • URGN $12.17
  • ALNT N/A
  • Revenue Next Year
  • URGN $44.23
  • ALNT $0.10
  • P/E Ratio
  • URGN N/A
  • ALNT $30.50
  • Revenue Growth
  • URGN 15.64
  • ALNT N/A
  • 52 Week Low
  • URGN $9.78
  • ALNT $16.91
  • 52 Week High
  • URGN $20.70
  • ALNT $36.33
  • Technical
  • Relative Strength Index (RSI)
  • URGN 40.55
  • ALNT 56.79
  • Support Level
  • URGN $9.86
  • ALNT $24.11
  • Resistance Level
  • URGN $11.87
  • ALNT $27.48
  • Average True Range (ATR)
  • URGN 0.50
  • ALNT 0.72
  • MACD
  • URGN -0.04
  • ALNT 0.14
  • Stochastic Oscillator
  • URGN 10.95
  • ALNT 74.05

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About ALNT Allient Inc.

Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.

Share on Social Networks: